Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy

被引：0

作者：

Arndt H. Brachat

Alexei A. Grom

Nico Wulffraat

Hermine I. Brunner

Pierre Quartier

Riva Brik

Liza McCann

Huri Ozdogan

Lidia Rutkowska-Sak

Rayfel Schneider

Valeria Gerloni

Liora Harel

Maria Terreri

Kristin Houghton

Rik Joos

Daniel Kingsbury

Jorge M. Lopez-Benitez

Stephan Bek

Martin Schumacher

Marie-Anne Valentin

Hermann Gram

Ken Abrams

Alberto Martini

Daniel J. Lovell

Nanguneri R. Nirmala

Nicolino Ruperto

机构：

[1] Novartis Institutes for Biomedical Research,

[2] Cincinnati Children’s Hospital Medical Center,undefined

[3] PRCSG,undefined

[4] Wilhelmina Kinderziekenhuis,undefined

[5] Department of Pediatric Immunology and Rheumatology,undefined

[6] Université Paris-Descartes,undefined

[7] IMAGINE Institute,undefined

[8] Hôpital Necker-Enfants Malades. Centre de référence national pour les Arthrites Juveniles,undefined

[9] Unité d’Immunologie,undefined

[10] Hématologie et Rhumatologie Pediatrique,undefined

[11] Rambam Medical Center,undefined

[12] Department of Pediatrics B,undefined

[13] Alder Hey Children’s NHS Foundation Trust,undefined

[14] Cerrahpasa Tip Fakultesi,undefined

[15] Ic Hastaliklari ABD,undefined

[16] Romatoloji BD,undefined

[17] Institute of Rheumatology,undefined

[18] Paediatric Clinic,undefined

[19] Hospital for Sick Children,undefined

[20] Division of Rheumatology,undefined

[21] Istituto Gaetano Pini,undefined

[22] Divisione di Reumatologia,undefined

[23] Schneider Childrens Medical Center,undefined

[24] Pediatric Rheumatology Unit,undefined

[25] Universidade Federal de São Paulo,undefined

[26] Pediatrics,undefined

[27] British Columbia Children’s Hospital,undefined

[28] Universitair Ziekenhuis Gent,undefined

[29] Centrum Voor Kinderreumatologie,undefined

[30] Randall Children’s Hospital at Legacy Emanuel,undefined

[31] Floating Hospital for Children,undefined

[32] Rheumatology NEMC 286,undefined

[33] Novartis Pharmaceuticals Corporation,undefined

[34] University of Genova and Istituto Giannina Gaslini,undefined

[35] Pediatria II-PRINTO,undefined

[36] Novartis Institutes for Biomedical Research,undefined

[37] Istituto Giannina Gaslini,undefined

[38] Pediatria II-PRINTO,undefined

来源：

Arthritis Research & Therapy | / 19卷

关键词：

Biomarkers; Canakinumab; Gene expression; Interleukin-1β; Juvenile idiopathic arthritis; SJIA;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[21] Safety and Effect of Canakinumab in Patients with systemic juvenile Arthritis
Burgess, Stephanie
AKTUELLE RHEUMATOLOGIE, 2019, 44 (02) : 93 - 93
[22] CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS PATIENTS AFTER SINGLE DOSE OF CANAKINUMAB
Wulffraat, N.
Kallinich, T.
McCann, L.
Brik, R.
Rutkowska-Sak, L.
Ferrandiz, M.
Lheritier, K.
Kim, D.
Gnanasakthy, A.
Ozdogan, H.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 266 - 267
[23] The safety of canakinumab in systemic juvenile idiopathic arthritis and autoinflammatory diseases in pediatric patients: a multicenter study
Coskuner, Taner
Caglayan, Senguel
Akgun, Ozlem
Torun, Ruya
Yayla, Emine Nur Sunar
Bagrul, Ilknur
Kilbas, Gulsah
Yener, Gulcin Otar
Kose, Hulya
Ozturk, Kubra
Baba, Ozge
Cakan, Mustafa
Demir, Ferhat
Sonmez, Hafize Emine
Kalyoncu, Mukaddes
Kilic, Sara Nsebnem
Yuksel, Selcuk
Baglan, Esra
Bakkaloglu, Sevcan A.
Unsal, Erbil
Aktay Ayaz, Nuray
Sozeri, Betul
EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (12) : 1299 - 1306
[24] CANAKINUMAB IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: CLINICAL INACTIVE DISEASE RATE AND SAFETY IN ITALIAN PATIENTS
Pardeo, Manuela
Bracaglia, Claudia
Piscitelli, Anna Lucia
De Matteis, Arianna
Tibaldi, Jessica
Alessio, Maria
Marino, Achille
Conti, Giovanni
Maggio, Maria Cristina
Alizzi, Clotilde
Licciardi, Francesco
Olivieri, Alma Nunzia
Filocamo, Giovanni
Orlando, Francesca
Martino, Silvana
Cimaz, Rolando
Ravelli, Angelo
De Benedetti, Fabrizio
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1345 - 1345
[25] Distinct Gene Expression Signatures Characterize Strong Clinical Responders Versus Nonresponders to Canakinumab in Children With Systemic Juvenile Idiopathic Arthritis
Verweyen, Emely L.
Pickering, Alex
Grom, Alexei A.
Schulert, Grant S.
ARTHRITIS & RHEUMATOLOGY, 2021, 73 (07) : 1334 - 1340
[26] Discontinuation of Canakinumab following Clinical Disease Remission Is Feasible in Patients with Systemic Juvenile Idiopathic Arthritis
Maritsi, Despoina N.
Vougiouka, Olga
Eleftheriou, Despina
JOURNAL OF RHEUMATOLOGY, 2020, 47 (04) : 634 - 635
[27] Distinct Gene Signature Predicts Strong Clinical Responses to Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis
Verweyen, Emely
Pickering, Alex
Grom, Alexei
Schulert, Grant
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[28] EFFICACY AND SAFETY OF CANAKINUMAB IN CHILDREN WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS WITH AND WITHOUT FEVER
Ruperto, N.
Brunner, H.
Quartier, P.
Constantin, T.
Alexeeva, E.
Kone-Paut, I.
Marzan, K.
Wulffraat, N.
Schneider, R.
Padeh, S.
Chasnyk, V.
Wouters, C.
Deschner, J. Kummerle
Kallinich, T.
Lauwerys, B.
Haddad, E.
Nasonov, E.
Trachana, M.
Vougiouka, O.
Abrams, K.
Leon, K.
Lheritier, K.
Martini, A.
Lovell, D.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 608 - 608
[29] Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience
Lingzhi Qiu
Le Ma
Yifan Xie
Jing Jin
Yuting Pan
Shumin Li
Zhidan Fan
Haiguo Yu
Pediatric Rheumatology, 22
[30] Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience
Qiu, Lingzhi
Ma, Le
Xie, Yifan
Jin, Jing
Pan, Yuting
Li, Shumin
Fan, Zhidan
Yu, Haiguo
PEDIATRIC RHEUMATOLOGY, 2024, 22 (01)

← 1 2 3 4 5 →